Cargando…
MDB-07. MYC AND TGFΒ PROMOTE GROUP 3 MEDULLOBLASTOMA TUMOR RESISTANCE THROUGH DEREGULATION OF KDM2B TARGETS
Medulloblastoma (MB) is one of the most prevalent malignant brain tumors in children, with tremendous cognitive and neuroendocrine disability among survivors. Group 3 (G3) MBs have poor overall survival at <50%, few recurrent mutations, higher frequency of metastasis, and no targeted therapies. A...
Autores principales: | Qadeer, Zulekha, Westelman, Samantha, Johnson, Mackenzie, Grele, Shane, Hou, Elise, Hendrikse, Liam, Wang, Linyu, Husain, Sarah, Beytagh, Mary Clare, Schmidt, Christin, Huang, Miller, Taylor, Michael, Weiss, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260175/ http://dx.doi.org/10.1093/neuonc/noad073.240 |
Ejemplares similares
-
MDB-09. IMPACT OF PRDM6 ON CHROMATIN ACCESSIBILITY, GENE EXPRESSION, AND MEDULLOBLASTOMA FORMATION
por: Schmidt, Christin, et al.
Publicado: (2023) -
MDB-37. CDK9 IS A DRUGGABLE MEDIATOR SUSTAINING MYC-DRIVEN TRANSCRIPTIONAL CIRCUITRY IN MEDULLOBLASTOMA
por: Krishna, Madhavan, et al.
Publicado: (2023) -
MDB-02. NUCLEAR ENVELOPE PHOSPHATASE CTDNEP1 MUTATIONS POTENTIATE AGGRESSIVE MEDULLOBLASTOMA BY TRIGGERING MYC ACTIVATION AND GENOMIC INSTABILITY
por: Lu, Richard, et al.
Publicado: (2023) -
MDB-42. UNCOVERING DYNAMIC CHANGES IN MEDULLOBLASTOMA ASSOCIATED VASCULATURE IN ZEBRAFISH
por: Morris, Elysse, et al.
Publicado: (2023) -
MDB-03. DFMO AS A TREATMENT STRATEGY IN GROUP 3 MEDULLOBLASTOMA
por: Shahab, Shubin, et al.
Publicado: (2023)